We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current OSL market cap is 14.66M. The company's latest EPS is AUD -0.0055 and P/E is -1.82.
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 2.85M | 1.44M | 1.06M | 1.47M | 1.46M |
| Operating Income | -4.36M | -10.4M | -10.58M | -11.45M | -12.13M |
| Net Income | -4.26M | -10.43M | -10.73M | -11.34M | -12.38M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 24.06M | 14.15M | 13.07M | 11.47M | 6.36M |
| Total Liabilities | 2.16M | 2.45M | 1.91M | 1.59M | 1.77M |
| Total Equity | 21.9M | 11.7M | 11.16M | 9.88M | 4.59M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -4.46M | -8.82M | -10.11M | -11.32M | -11.13M |
| Investing | -21k | -54k | -6k | -58k | N/A |
| Financing | 17.79M | 111k | 9.16M | 9.49M | 6.24M |
| Market Cap | 14.66M |
| Price to Earnings Ratio | -1.82 |
| Price to Sales Ratio | 16.67 |
| Price to Cash Ratio | 5 |
| Price to Book Ratio | 4.91 |
| Dividend Yield | - |
| Shares Outstanding | 2.26B |
| Average Volume (1 week) | 3.42M |
| Average Volume (1 Month) | 5.94M |
| 52 Week Change | -27.78% |
| 52 Week High | 0.015 |
| 52 Week Low | 0.004 |
| Spread (Intraday) | 0 (14.29%) |
| Company Name | Oncosil Medical Ltd |
| Address |
suite 503 north sydney, new south wales 2060 |
| Website | https://www.oncosil.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
